Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Adipotide (FTPP) (FTPP) is a metabolic peptide, at the preclinical stage in the published literature. Adipotide (FTPP - Fat-Targeted Proapoptotic Peptide) is a chimeric peptidomimetic designed to induce targeted fat loss by selectively destroying the blood supply to white adipose tissue. Developed at MD Anderson Cancer Center and the University of Texas, it represents a fundamentally different approach to obesity treatment — rather than suppressing appetite or blocking fat absorption, it physically eliminates fat tissue by cutting off its blood supply. In a landmark 2012 study in obese rhesus monkeys, Adipotide treatment led to 11% body weight loss and 39% reduction in abdominal fat over 4 weeks, with improved insulin resistance. However, reversible kidney toxicity was observed, and the compound has not progressed to human trials.
Adipotide (FTPP - Fat-Targeted Proapoptotic Peptide) is a chimeric peptidomimetic designed to induce targeted fat loss by selectively destroying the blood supply to white adipose tissue. Developed at MD Anderson Cancer Center and the University of Texas, it represents a fundamentally different approach to obesity treatment — rather than suppressing appetite or blocking fat absorption, it physically eliminates fat tissue by cutting off its blood supply. In a landmark 2012 study in obese rhesus monkeys, Adipotide treatment led to 11% body weight loss and 39% reduction in abdominal fat over 4 weeks, with improved insulin resistance. However, reversible kidney toxicity was observed, and the compound has not progressed to human trials.
| Research Status | Preclinical |
|---|---|
| Half-Life | Variable (peptidomimetic) |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 0.5-1.0 mg/kg (research dosing) |
| Molecular Weight | ~2,500 Da |
Adipotide contains a targeting sequence (CKGGRAKDC) that binds prohibitin on the surface of blood vessels in adipose tissue, fused to a pro-apoptotic peptide (D(KLAKLAK)2) that disrupts mitochondrial membranes, causing vascular endothelial cell death and subsequent fat tissue resorption.
Adipotide (FTPP - Fat-Targeted Proapoptotic Peptide) is a chimeric peptidomimetic designed to induce targeted fat loss by selectively destroying the blood supply to white adipose tissue. Developed at MD Anderson Cancer Center and the University of Texas, it represents a fundamentally different approach to obesity…
Adipotide contains a targeting sequence (CKGGRAKDC) that binds prohibitin on the surface of blood vessels in adipose tissue, fused to a pro-apoptotic peptide (D(KLAKLAK)2) that disrupts mitochondrial membranes, causing vascular endothelial cell death and subsequent fat tissue resorption.
Adipotide (FTPP) is at the following stage in the published literature: Preclinical. All information is for research and educational purposes only.
Reported half-life: Variable (peptidomimetic).
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.